Beijing Mabworks Biotech Co., Ltd.
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS7
PHASE 3 / 2-32
RECRUITING4
READOUTS ≤12 MONTHS0
| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| Recombinant Humanized Monoclonal Antibody MIL62 Injection NCT07044115 |
P1/2 | Active, not recruiting | Lupus Nephritis | 41 | 2025-01-16 |
| MIL62 NCT05314010 |
P3 | Active, not recruiting | Neuromyelitis Optica Spectrum Disorder | 102 | 2025-02-21 |
| MBS303 NCT05806099 |
P1/2 | Recruiting | Non-Hodgkin's Lymphoma | 132 | 2025-11 |
| MBS314 Injection NCT06232096 |
P1/2 | Recruiting | Relapsed or Refractory Multiple Myeloma | 154 | 2026-02 |
| MBS314 for Injection NCT07911748 |
P1/2 | Not yet recruiting | Multiple Myeloma | 78 | 2027-12 |
| MIL116 NCT07375758 |
P1/2 | Recruiting | Immunoglobulin A Nephropathy | 130 | 2028-06 |
| MIL62 NCT07405970 |
P3 | Recruiting | Systemic Lupus Erythematosus | 316 | 2028-12 |